624 results about "Protein antibody" patented technology

Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibodies to IL-1-R intracellular ligand proteins are disclosed. The antibodies arc useful for inhibiting the binding between IL-1-R and IL-1-R intracellular ligand proteins.

The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that bind to α2 integrin without activating platelets.

This invention discloses one EPSPS gene enzyme immune agent case and its use method in the anti-herbicide bean, wherein, the case comprises anti-EPSPS multi-clone antigen, enzyme board with the antigen, enzyme antigens for two, gene switch bean standard product, non-transfer gene bean standard, intense wash liquid, develop liquid and terminal liquid. This invention method comprises the following steps: cloning CP4-EPSPS gene from the gene switch bean expressed in the bacillus coli; then through protein purification complex property to regroup EPSPS protein antibody immune animal to get special single clone antigen and multi-clone antigen; establishing double antigen clamp enzyme immune system test sample to determine its EPSPS protein content.

The present invention discloses a nucleic acid aptamer, wherein the sequence of the nucleic acid aptamer comprises a DNA segment represented by any one sequence selected from a sequence 1, a sequence 2 and a sequence 3. The nucleic acid aptamer can further be various similar sequences with high homology or a derivative obtained from the sequence of the present invention. The invention further discloses a nucleic acid aptamer screening method, which comprises: synthesizing a random single-stranded DNA library and primers, carrying out SELEX screening, carrying out PCR amplification of library, preparing a DNA single strand library, and finally carrying out repeated screening, negative screening and multi-round screening to obtain the nucleic acid aptamer. The nucleic acid aptamer and the derivative thereof can be used in recognition of the prostate cancer cell strain PC-3 or preparation of kits, molecular probes and targeted mediums for prostate cancer detection, and can further be used in design and preparation of prostate cancer treatment drugs. Compared with the protein antibody, the nucleic acid aptamer of the present invention has advantages of high affinity, high specificity, no immunogenicity, capability of being chemically synthesized, small molecular weight, stability, easy storage, easy labeling and the like.

The invention discloses a new antibody as anti-A beta-1-32 starch protein antibody of human beings, which also provides a purifying method of antibody and application in the relative disease with original and secondary starch degenerating disease, especially for senile dementia and diagnosis.

Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.

Disclosed is a neutrophil gelatinase-associated lipocalin (NGAL) protein level ELISA kit which is composed of a reagent I and a reagent II. The reagent I comprises a slow-release agent and a denaturant; the reagent II comprises latex particles coated with NGAL antibodies. Aggregated protein is denatured to some extent after being added with the denaturant, physical and (or) chemical binding site is exposed, chemical binding action of the chemical binding site is fractured through sulfydryl dissociation agent , while physical binding action of the physical binding site is dispersed by surface active agent, so that the aggregated protein is disaggregated. Therefore, it is quite important to choose the appropriate types and concentrations of denaturant, sulfydryl dissociation agent, and surface active agent; the aggregate is disaggregated without interference on following immunological detection. According to the method, the the appropriate types and concentrations of denaturant, sulfydryl dissociation agent and surface active agent are determined and chosen specifically, which solves the technical problem above.

The invention relates to an electrochemiluminescence immunosensor for detecting beta-amyloid protein and construction of the electrochemiluminescence immunosensor. The sensor comprises a magnetic glassy carbon electrode and Fe3O4-expoxy, a mesoporous carbon @Ru(bpy)32+/beta-amyloid protein antibody composite nanometer composite material, beta-amyloid protein to be detected with different concentrations and a gold nanorod-beta- beta-amyloid protein aptamer nanometer composite material, wherein the Fe3O4-expoxy, the mesoporous carbon @Ru(bpy)32+/beta-amyloid protein antibody composite nanometer composite material, beta-amyloid protein to be detected with different concentrations and the gold nanorod-beta- beta-amyloid protein aptamer nanometer composite material are synthesized on the surface of the magnetic glassy carbon electrode in sequence. Compared with the prior art, the electrochemiluminescence immunosensor has the advantages that the constructing method is simple, detection on Alzheimer's disease markers (beta-amyloid protein and the like) is high in speed, high in sensitivity, high in specificity, low in detection limit, wide in detection range and the like, and the application of the electrochemiluminescence immunosensor provides a new thought for early diagnosis of the Alzheimer's disease and detection of markers of other diseases.

The invention discloses a cyclic chimeric citrullinated peptide antigen and an application thereof. The preparation of the cyclic chimeric citrullinated peptide antigen comprises the following steps: firstly connecting and jogging three small-molecular antigen peptides, namely a citrullinated peptide1, a citrullinated peptide 2 and a citrullinated peptide 3 derived from a silk polymerizing protein/an intermediate filament protein, and then synthetizing a cyclic polypeptide with a similar protein beta-corner structure by forming a disulfide bond through two cysteines inserted into the end N and the end C of a chimeric peptide. The cyclic chimeric citrullinated peptide antigen coats a solid-phase vector to prepare an indirect enzyme linked immunosorbent assay kit used for detecting the hypotype of multiple anti-citrullinated protein antibodies contained in RA (Rheumatoid Arthritis) serum. The cyclic chimeric citrullinated peptide antigen and the ELISA kit thereof which are disclosed by the invention have the advantages of simple preparation and experimental operation process, good result repeatability, qualification or quantification and wide clinical application and scientific research value and are outstandingly enhanced in detection sensibility and diagnosis value on RA compared with an international similar kit.

This application includes, in part, methods of preparing antibodies that specifically bind to tnethylation-controlling J (MCJ) polypeptide. In some aspects, the application also includes, hybridoma cell lines that produce antibodies that specifically MCJ polypeptide; antibodies and antigen-binding fragments thereof produced with the methods of the application,—and methods of using antibodies and antigen-binding fragments that specifically bind MCJ polypeptide for diagnosis and treatment of cancer.

The invention relates to an immunochromatographic kit for rapidly detecting novel coronavirus N protein as well as a preparation method and application of the immunochromatographic kit. The immunochromatographic kit comprises a test strip, the test strip comprises a detection line and a quality control line, the detection line is coated with an anti-novel coronavirus N protein antibody, and the quality control line is coated with a goat anti-rabbit polyclonal antibody. The immunochromatographic kit for rapidly detecting the novel coronavirus N protein provided by the invention can be used fordetecting the novel coronavirus N protein in a nasopharynx swab, an oropharynx swab, an alveolar lavage fluid, an oral swab or a saliva sample so as to be used for diagnosing novel coronavirus pneumonia.

The invention discloses a technology for producing a recombinant antibody protein through the high density perfusion culture of hybridoma cells. The technology which aims at the metabolic characteristic of the hybridoma cells screens a specific culture component for the perfusion culture, and allows metabolic substrates to be fully supplied in the culture process and the concentration of metabolic byproducts to be simultaneously and effectively reduced, so objects of high efficiency and high yield is reached. In the process control aspect, a specific perfusion rate CSPR perfusion culture calculating model is established to carry out real time calculation on culture parameters, and concentrated medium subsection fed batch is adopted to control the perfusion rate, so important substrates ofglucose and glutamine are supplied and the influence of the byproducts to culture is minimized. The technology which is suitable for the preparation of the production antibody protein through the large scale culture of the hybridoma cells allows a large amount of protein antibodies to be provided in a short time, has the advantages of small scale, low investment, realization of the high efficiency output in a short time, low batch difference, high repeatability, and realization of the production of antibody medicines.

The invention discloses a magnetic particle chemiluminescence quantitative assay kit for anti-ribosomal P protein antibody IgG. The kit includes: anti-ribosomal P protein antibody IgG calibrator; Ribosomal P protein antigen and bovine serum albumin-labeled Tris buffer; alkaline phosphatase-labeled goat anti-human polyclonal antibody and bovine serum albumin in Tris buffer; streptavidin-labeled magnetic particles and bovine serum albumin Serum albumin in Tris buffer; wash solution. Based on the traditional membrane strip immunoassay and enzyme-linked immunosorbent assay, the detection method of the kit increases the sensitivity and linear range by 3-5 orders of magnitude, and realizes quantitative detection in a real sense, with rapid response, reliable results, and It can be used in conjunction with a fully automatic chemiluminescence immunoassay analyzer to realize fully automatic use, and has irreplaceable important value for clinical diagnosis.

The invention discloses infective clone for porcine circovirus type 1 and rescued virus and application thereof. Two genomes of the porcine circovirus type 1 are connected in cis and inserted into a vector to construct and obtain an infective molecular clone. A Sal I enzyme cutting site as a molecular target is inserted in the infective molecular clone. A rescued recombinant virus (PCV1/G strains) carries a molecular marker, and the preservation number of the rescued recombinant virus is CGMCC NO.2658. An antigen of the recombinant virus is only reacted with a univalent specific antibody of PCV1/Cap protein, but has no cross with an antibody against PCV2/Cap protein. The recombinant virus and a parental virus are identified by combination of PCR and RFLP. The virus strain cultured in vitro has stable propagation property and high virus titer, and the rescued virus strain can be used for detecting the antibody of the virus. The invention lays a foundation for research such as genesis and evolution, genetic variation rule, molecular differential diagnosis, and the like for porcine circovirus in future.

The invention relates to peptides derived from HBV L protein for the prevention and treatment of Hepatitis B virus (HBV) infection, screening method for removing antigenicity of these peptides and the deantigenic derivative peptide screened through the method, wherein the HBV surface L protein pre-S1 region contains key amino acid sequence of the virus adhesion cell surface acceptor and antigenic amino acid sequence bonding with the anti-L protein antibody. The polypeptides at the HBV surface L protein pre-S1 region can suppress HBV infection to cells. The invention also provides the screening method for removing the antigenicity of these polypeptides.

The invention relates to a method for quantitatively detecting alpha-synuclein auto-antibodies in human sera, and prepares recombinant human alpha-synuclein as antigens and rabbit anti-human alpha-synuclein polyclonal antibodies as antibodies into a kit, wherein, the quantities of alpha-synuclein auto-antibodies in the sera of patients with Parkinson's disease (PD) and in the sera of normal healthy persons are detected by utilizing the antigen-antibody reaction principle and are compared; and the presence and quantity of alpha-synuclein auto-antibodies in human sera are judged by the kit on the basis of color reaction.

The invention discloses an affinity absorption column for specially removing virions from blood and preparing method thereof, in particular relates to an affinity absorption column for blood purification. The affinity absorption column comprises an absorption carrier, an activator and antivirus surface protein antibody; the activator is added into the absorption carrier to obtain an activated carrier; the antivirus surface protein antibody is added into the activated carrier to perform antibody coupling to obtain an immune absorber, and the immune absorber is loaded into the absorption column to obtain the affinity absorption column. The affinity absorption column has the advantages of strong specificity, little toxic side effect, good therapeutic effect, good repeatability and low cost, and is suitable for blood purification; besides, being a separation technology, the affinity absorption column can be widely applied to other fields for the purification and separation of virus antibodies.

The invention discloses a test strip for detecting infectious bovine rhinotracheitis, which comprises a PVC backboard, a sample pad, a gold mark pad, a cellulose membrane and a water absorbing pad. The test strip is characterized in that infectious bovine rhinotracheitis virus gD protein according to the claim 1, marked by colloidal gold, is coated on the gold mark pad; and the infectious bovine rhinotracheitis virus gD protein and a rabbit anti-infectious bovine rhinotracheitis virus gD protein antibody are separately coated on a detection line and a quality control line of the cellulose membrane. The test strip for detecting the infectious bovine rhinotracheitis virus antibody in a bovine serum sample is high in sensitivity, is good in specificity, is quick and convenient to detect, is easy to use, and is free of special apparatus equipment, can detect results within 10 minutes, and is very convenient for being popularized and used in the basic-level breeding unit.